Search Results | NIH

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Search Results 2521 – 2540 of 3242

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/bartonellosis

Table 2. Treatment of HIV-Associated Opportunistic Infections (Includes Recommendations for Acute Treatment and Secondary Prophylaxis/Chronic Suppressive/Maintenance Therapy)

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/treatment-hiv-associated

Dolutegravir (Tivicay, DTG)

https://clinicalinfo.hiv.gov/guidelines/perinatal/safety-toxicity-arv-agents-integrase-inhibitors-dolutegravir-tivicay

Special Considerations for Antiretroviral Therapy Use in Adolescents With HIV

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/specific-considerations-antiretroviral-therapy-use-adolescents-hiv

Lactic Acidosis

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/lactic-acidosis

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/lamivudine

Protease Inhibitors (PIs)

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-arv/protease-inhibitors-pis

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/atazanavir

Tipranavir (Aptivus, TPV)

https://clinicalinfo.hiv.gov/guidelines/perinatal/archived-drugs-tipranavir-aptivus

Special Populations: HIV-2 Infection

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/special-populations-hiv-2-infection

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/appendices

Appendix B. Important Guideline Considerations

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/appendix-important-considerations

Isosporiasis (Cystoisosporiasis)

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/isosporiasis

Emtricitabine (Emtriva, FTC)

https://clinicalinfo.hiv.gov/guidelines/perinatal/safety-toxicity-arv-agents-nrtis-emtricitabine-emtriva

Entry and Attachment Inhibitors

https://clinicalinfo.hiv.gov/guidelines/perinatal-hiv-clinical-guidelines/entry-and-attachment-inhibitors

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/dolutegravir

Virologic Failure

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/virologic-failure

Lopinavir/Ritonavir

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/lopinavirritonavir

Doravirine (Pifeltro, DOR)

https://clinicalinfo.hiv.gov/guidelines/perinatal/safety-toxicity-arv-agents-nnrtis-doravirine-pifeltro

Adverse Effects of Antiretroviral Medications

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/adverse-effects-antiretroviral-medications